Why are liver checks necessary with bosentan?

Bosentan is an endothelin‑receptor antagonist that’s very effective for treating pulmonary arterial hypertension (PAH), but it carries a notable risk of liver injury. Because of that, routine liver‑function testing is a mandatory part of the treatment plan.

Why the liver matters

How the monitoring works

1. Baseline test – Before starting bosentan, doctors check ALT, AST, alkaline phosphatase (ALP), bilirubin, and sometimes total protein.
2. Regular intervals –
   • Every 2 weeks for the first 3 months.
   • Every 3 months thereafter, provided levels remain normal.
3. What to watch for –
   • ALT/AST ≥ 3× the upper‑limit of normal (ULN) or a ≥ 3× increase from baseline → bosentan is usually stopped.
   • Bilirubin ≥ 3× ULN or ≥ 3× increase from baseline → also leads to discontinuation.
   • If levels rise between 1.5–3× ULN, a clinician may reduce the dose (from 62.5 mg to 31.25 mg daily) and repeat testing in 2 weeks.
4. Re‑initiation – After normalisation of LFTs, bosentan can sometimes be restarted at a lower dose, but this is decided on a case‑by‑case basis.

Who’s at higher risk?

• Age > 60 years
• Pre‑existing liver disease (viral hepatitis, fatty liver)
• Concurrent hepatotoxic drugs (e.g., some antifungals, methotrexate)
• Heavy alcohol use

If you’re on bosentan, your doctor will take these factors into account when deciding on the monitoring schedule and whether dose adjustments are needed.

Bottom line

Liver checks are necessary with bosentan because the drug can cause serious, sometimes reversible liver injury. Regular monitoring ensures any rise in liver enzymes is caught early, allowing prompt dose adjustment or discontinuation before the injury progresses. This vigilance keeps the therapy safe while still giving you the benefits of improved pulmonary circulation.